Medlab Clinical Ltd
ASX:MDC
Intrinsic Value
Medlab Clinical Ltd. engages in the development of therapeutic pathways for diagnosed chronic diseases. [ Read More ]
The intrinsic value of one
MDC
stock under the Base Case scenario is
5.76
AUD.
Compared to the current market price of 6.6 AUD,
Medlab Clinical Ltd
is
Overvalued by 13%.
MDC's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
MDC or that its price is influenced by factors unrelated to fundamentals.
Medlab Clinical Ltd's market capitalization is 15.1m AUD.
MDC stock price is 6.6 AUD.
MDC stock (5.76 AUD) is 13% less than its price (6.6 AUD).
MDC. Open DCF Valuation
MDC stock (5.76 AUD) is 13% less than its price (6.6 AUD). Open Relative Valuation
MDC has upside potential of 185% compared to the average analyst price target.
Open Wall St Estimates
MDC's short-term assets (3m AUD) exceed its short-term liabilties (2m AUD).
MDC's long-term assets (3m AUD) exceed its long-term liabilties (2m AUD).
MDC's Revenue has dropped by 29% over the past 12 months.
MDC's ROE (Return on Equity) has significantly decreased in the last 3 years from -111% to -145%, and is approaching profitability.
MDC's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -225% to -197%, and is approaching profitability.
MDC has negative Operating Income for the last twelve months.
MDC has negative Net Income for the last twelve months.
MDC's ROE (Return on Equity) for the past 12 months is negative and is equal to -145%.
MDC's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -197%.
MDC has positive Gross Profit for the last twelve months.
MDC has negative Free Cash Flow for the last twelve months.
MDC's Revenue has been falling by 31% per year for the last 3 years.
MDC has negative three-year average ROE (Return on Equity): -90%. The company is not efficient at transforming stockholders' equity into net income.
MDC has negative three-year average ROIC (Return on Invested Capital): -220%. The company is not efficient at using invested capital to generate operating income.
MDC's D/E (Debt to Equity) is very low and is equal to 0.
MDC's Altman Z-Score is very low and is equal to -31.27.
MDC earns more than enough operating income (-7m AUD) to safely cover interest payments on its debt (-33k AUD).
Valuation Backtest
Medlab Clinical Ltd
Run backtest to discover the historical profit from buying and selling
MDC
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Medlab Clinical Ltd
Balance Sheet Decomposition
Medlab Clinical Ltd
| Current Assets | 3.1m |
| Cash & Short-Term Investments | 226k |
| Receivables | 2.9m |
| Non-Current Assets | 50k |
| Other Non-Current Assets | 50k |
| Current Liabilities | 1.9m |
| Accounts Payable | 1.2m |
| Accrued Liabilities | 322.8k |
| Other Current Liabilities | 310.4k |
| Non-Current Liabilities | 13.8k |
| Other Non-Current Liabilities | 13.8k |
Earnings Waterfall
Medlab Clinical Ltd
|
Revenue
|
943.7k
AUD
|
|
Cost of Revenue
|
-91.1k
AUD
|
|
Gross Profit
|
852.6k
AUD
|
|
Operating Expenses
|
-8.1m
AUD
|
|
Operating Income
|
-7.2m
AUD
|
|
Other Expenses
|
446.4k
AUD
|
|
Net Income
|
-6.8m
AUD
|
Free Cash Flow Analysis
Medlab Clinical Ltd
MDC Profitability Score
Profitability Due Diligence
Medlab Clinical Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Medlab Clinical Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
MDC Solvency Score
Solvency Due Diligence
Medlab Clinical Ltd's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
Medlab Clinical Ltd's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MDC Price Targets Summary
Medlab Clinical Ltd
According to Wall Street analysts, the average 1-year price target for
MDC
is 18.84 AUD
.
Shareholder Return
MDC Price
Medlab Clinical Ltd
| Average Annual Return | -29.62% |
| Standard Deviation of Annual Returns | 14.49% |
| Max Drawdown | -92% |
| Market Capitalization | 15.1m AUD |
| Shares Outstanding | 2 283 502 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Medlab Clinical Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Medlab Clinical Ltd. engages in the development of therapeutic pathways for diagnosed chronic diseases. The company is headquartered in Alexandria, New South Wales. The company went IPO on 2015-07-14. Medlab’s pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The firm's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use. The firm also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory. NanoCelle is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia, United States, and the United Kingdom.
Contact
IPO
Employees
Officers
The intrinsic value of one
MDC
stock under the Base Case scenario is
5.76
AUD.
Compared to the current market price of 6.6 AUD,
Medlab Clinical Ltd
is
Overvalued by 13%.
You don't have any saved screeners yet
